



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 27-10-2008

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 08-11-2008 TO BE PUBLISHED 18-11-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 27-10-2008

To,

Mr. Manzoor Ahmed
Section Officer
Cabinet Secretariat
Cabinet Division
Government of Pakistan
Islamabad

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 08-11-2008 TO BE PUBLISHED 18-11-2008 IN THE
GAZETTE OF PAKISTAN PART-V.**

Reference to Cabinet Secretariats letter No. 18/IPO/2008/RA-IV, dated 23rd April 2008. A manuscript copy of the weekly notification regarding application filed, application accepted and sealing fee due etc., is enclosed herewith for onward transmission to the Printing Corporation of Pakistan Press for publication in the next issue of the Gazette of Pakistan Part-V.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

1305/2008	<u>03-11-2008</u> Air Commodore Zahoor Akram Shaikh, Karachi, Pakistan	“The liquid motor”
1306/2008	Schering Corporation, USA (Priority 05-11-07 USA)	“Gama Secretase modulators”
1307/2008	Takeda Pharmaceutical Company, Limited. Japan (Priority 11-11-07 USA)	“MAPK/ERK Kinase inhibitors”
1308/2008	LES Laboratoires Servier France (Priority 09-11-07 France)	“New crystalline form VI of agomdlatine, a process for its preparation and pharmaceutical compositions containing it”
1309/2008	<u>04-11-2008</u> Novartis AG, Switzerland (Priority 06-11-07 USA)	“Pharmaceutical compositions”
1310/2008	Novartis AG, Switzerland (Priority 05-11-07 USA)	“Organic compounds
1311/2008	<u>05-11-2008</u> Huawei Technologies Co., Ltd. China (Priority 05-11-07 China)	“Method, system, and device for automatic call forwarding”
1312/2008	1. Otsuka Pharmaceutical Co., Ltd. 2. Hirofumi Takeuchi Japan (Priority 08-11-07 Japan)	“Nucleic acid complex and nucleic acid delivery composition”
1313/2008	Honda Motor Co., Ltd. Japan (Priority 19-12-07 Japan)	“Motorcycle front cowl structure”

1314/2008	AstraZeneca AB, Sweden (Priority 06-11-07 USA)	“Novel compound 089”
1315/2008	Schering Corporation, USA (Priority 07-11-07 USA)	Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors”
1316/2008	Smithkline Beecham Biological S.A., Belgium (Priority 16-10-98 UK)	“ Process for the preparation of vaccine compositions”
	<u>06-11-2008</u>	
1317/2008	Clipsal Australia Pty Limited, Australia	“A cable manager for managing cables terminating in rack mounted patch panels and the like”
1318/2008	Pfizer Inc., USA (Priority 06-11-07 USA)	“Cycloalkylamino acid derivatives”
1319/2008	LG Life Science Ltd. Korea, (Priority 12-9-08 Korea)	“Composition for detection of M. tuberculosis complex or mycobacteria genus and simultaneous detection methods for M. tuberculosis complex and mycobacteria genus with multiplex real time PCR using the same”
1320/2008	N.V. Organon Netherlands (Priority 07-11-07 Europe)	“Intrauterine deposit”
1321/2008	N.V. Organon Netherlands (Priority 13-11-07 Europe)	“Heterocyclic derivatives”
1322/2008	SmithKline Beecham Corporation, USA (Priority 09-11-07 USA)	“Peptide deformylase inhibitors”
	<u>07-11-2008</u>	
1323/2008	AstraZeneca AB, Sweden (Priority 09-11-07 USA)	“Package 044”

1324/2008	Sanofi-Aventis France (Priority 09-11-07 France)	“Process for the preparation of morphine compounds”
1325/2008	Vifor (International) AG, Switzerland (Priority 16-11-07 Europe)	“Pharmaceutical compositions”
	<u>08-11-2008</u>	
1326/2008	1. M. Kashif 2. M. Babar Akbar, Karachi, Pakistan	“Bike security device controlled by different on/off operating system”
1327/2008	Honda Motor Co., Ltd., Japan (Priority 21-11-07 Japan)	“Vehicular power supply system”
1328/2008	Enanta Pharmaceuticals, Inc., USA (Priority 14-11-07 USA)	“Quinoxaline-containing compounds as hepatitis C virus inhibitors”
1329/2008	Glaxo Group Limited, UK (Priority 08-11-07 USA)	“Pharmaceutical formulations”

☒☒☒☒☒☒☒

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

996/1998	SmithKline Beecham Biological S.a., Belgium	“A vaccine composition comprising HIV protein, pharmaceutical composition containing it” A61K 39/285 139849
----------	---	---

The invention provides (a) an HIV Tat protein linked to either (i) a fusion partner or (ii) and HIV nef protein or or (b) an HIV Nef protein or linked to either (i) a fusion partner or (ii) an HIV Tat protein or (c) an HIV Nef protein linked to an HIV Tat protein and a fusion partner. The invention further provides for a nucleic acid encoding such a protein and a host cell, such as pichia pastoris, transformed with the aforementioned nucleic acid.

511/2003	Wyeth, USA.	“Novel formate salt of O-desmethyl-venlafaxine” A61K 9/22 139850
----------	----------------	---

A novel salt of O-desmethylvenlafaxine, O-desmethylvenlafaxine formate, is provided. Pharmaceutical composition dosage form and method of use are also provided.

462/2005


Pfizer Inc.,
USA.

“New aminopyridine compound”

CO7D 213/73, CO7D 401/04

139851

The present invention provides for compound of formula (I):



which is a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. This compound is useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD; lack of interest in sex), female orgasmic disorder (FOD; inability to achieve orgasm); and male sexual dysfunction, in particular male erectile dysfunction (MED). Male sexual dysfunction as referred to herein is meant to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or desire disorders such as hypoactive sexual desire disorder (HSDD; lack of interest in sex). This compound is also useful in treating neuropsychiatric disorders and neurodegenerative disorders.

770/2005

Dystar Textilfarben
GmbH & Co.
Deutschland KG.,
Germany

“A quinoneimine sulfur dye composition for dyeing cellulosic material”

CO9B 49/00

139852

Novel leuco sulfur dye composition obtainable at current densities between 50 mA/cm² and 500 mA/cm² and a flow velocity in the range from 0.1 m/s and preferably in the range from 0.1 to 0.4 m/s, its production and use for dyeing

cellulosic material.

1052/2007 Alfa Wassermann
S.p.A.,
Italy

“Polyol compound to stabilize polymorphous form of rifaximin”

A61K 9/16

139853

Polyol stabilize polymorphous form of Rifaximin, in particular the B form. When polyol having at least two hydroxy groups are added to rifaximin powder, polymorph B is stable and remains stable in time independently from the environment humidity.

④④④④④④④④

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139504	Bayer Aktiengesellschaft., Germany	999/1998
139505	Otsuka Pharmaceutical Co.Limited., Japan	1290/1998
139506	Pfizer Inc., USA	967/1999
139507	Janssen Pharmaceutica N.V. Belgium	580/2000
139508	F. Hoffmann-La Roche AG., Sfitzerland	810/2000
139509	Celanese International Corporation., USA	152/2005
139510	Reckitt Benckiser (UK) Limited., United Kingdom	174/2005
139511	Novartis AG., Switzerland	705/2005

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488